Особенности коррекции эректильной дисфункции у больных артериальной гипертензией
Диссертация
Результаты работы внедрены и используются в практической деятельности врачей урологических и терапевтических отделений ГКБ № 50 Департамента здравоохранения Правительства Москвы, на кафедрах урологии с курсами андрологии и урогинекологии и клинической фармакологии МГМСУ. По материалам диссертации подготовлены и утверждены в Департаменте здравоохранения Правительства Москвы методические… Читать ещё >
Список литературы
- Арабидзе Г. Г., Арабидзе Гр. Г. Антигипертензивная терапия и половая функция у мужчин // Клин. Фарм. Тер. 1999. — N 3. — С. 4952.
- Бавильский А.Ф. Локальное отрицательное давление в диагностике и лечении эректильной недостаточности: Дис.. канд. мед. наук. Челябинск, 1997. — 129 с.
- Вёрткин А.Л., Лоран О. Б., Тополянский A.B., Носовицкий П. Б., Жиленко В. В. Эректильная дисфункция у кардиологических и терапевтических пациентов // Русский Медицинский Журнал. Том 10, № 28, 2002.
- Горпинченко И.И., Бойко М. И., Першуков О. И., Прощаков К. В. Использование вазоактивного препарата «Эдекс» для лечения больных с эректильной дисфункцией // Урология (Киев). 1998, № 1. — С. 78−80.
- Иванов В.Н., Мягков Ю. А., Аплетаев В. В. Современная диагностика и лечение ЭД // Воен.-мед. журн. 2000, № 1. — С. 39−46.
- Калиниченко С. Ю., Козлов Г. И., Мельниченко Г. А, Дедов И. И. Опыт применения силденафила цитрата (Виагры) у пациентов с сахарным диабетом // Тер. Архив. 1999, N10. — С.78−80.
- Калиниченко С.Ю., Козлов Г. И., Дедов И. И. Опыт комплексного подхода к лечению ЭД // Рус. мед. журн. 2000. — Т. 9, № 11−12.-С. 18−21.
- Калиниченко С.Ю., Козлов Г. И., Дедов И. И. Опыт применения Виагры в у больных с сахарным диабетом // Тер. архив. 1999. — № 10. -С. 78−80.
- Ковалев В.А., Королева С. В., Комолов А, А. Фармако-терапия эректильной дисфункции // Урология. 2000. — N1. — С. 33−38.
- Ковалев В.А., Королева C.B. Отдаленные результаты реконструктивных сосудистых операций при васкулогенной ЭД // Материалы 9-го Всерос. съезда урологов. Курск. — 1997. — С. 463−464.
- Коган М.И., Зимин О. Н., Сизякин Д. В. Венозная гемодинамика полового члена у молодых мужчин с ЭД // Андрология. — 2000. -№ 1.-С.72.
- КоролеваС.В., КовалевВ. А, КачаловАА, ЕфрелювЕ. А Фармакотерапия эректильной дисфункции. История. Современное состояние проблемы // Андрология и генитальная хирургия. 2000. — N1. -С. 113−114.
- Красулин В.В., Серебренников С. М. Хирургическое лечение эректильной импотенции // Ростов н/Д. 1994. — 96 с.
- Кротовский Г. С. Лечение сосудистой импотенции // М.: СПб., 1998.- 190 с.
- Кротовский Г. С. Медикаментозное лечение эректильных дисфункций II-М.: БИНОМ. 1998. — 127 с.
- Кротовский Г. С., Зудин A.M. Виагра 5 лет успеха // - М. -2003.- 189 с.
- Кротовский Г. С., Учкин И. Г., Зудин A.M. Патогенез, диагностика и хирургическое лечение патологического венозного дренажа кавернозных тел // Андрология. 2000. — № 2. — С. 21−25.
- Литвицкий П.Ф. Патофизиология // М., 1997. 1999 с.
- Лопаткин H.A. Руководство по урологии в трёх томах // М., 1998
- Лоран О. Б., Аляев Ю. Г., Щеплев П. А. и др. Виагра (силденафила цитрат) в лечении больных с эректильной дисфункцией // Урология. 2000. — N 1. — С. 30- 33.
- Лоран О.Б., Сегал A.C. Климактерические расстройства у мужчин // М. 1999. — 88 с.
- Лоран О.Б., Сегал A.C. Шкала количественной оценки мужской копулятивной функции (шкала МКФ). // Урология и нефрология. 1998. — № 5. С. 24−27.
- Лоран О.Б., Сегал A.C., Дзагоев А. Г., Ковынев A.B. Влияние йохимбина на региональную гемодинамику полового члена по данным динамической ангиопенисцинтиграфии.//Материалы 9-го Всероссийского съезда урологов. Курск. 1997. — С.468.
- Лоран О.Б., Сегал A.C., Щеплёв П. А. Простагландин El в диагностике и терапии нарушений эрекции. // Урология и нефрология. — 1995.-№ 4.-с. 35−38.
- Лоран О.Б., Щеплев П. А., Кухаркин С. А., Абдуллаев И. А. Диагностика и лечение эректильных дисфункций // Анналы хирургии. М., 1998. -№ 4. -С. 5−10.
- Лоран О.Б., Щеплев П. А., Нестеров С. Н. и др. Методические рекомендации по диагностике и лечению эректильных функций. М., 1999.-С. 5−6.
- Лоран О.Б., Щеплев П. А., Нестеров С. Н., Кухаркин С. А. Современные методы диагностики и лечения эректильных дисфункций // Русский Медицинский Журнал. Том 8, № 3. — 2000. — С. 130−134.
- Мазо Е.Б., Дмитриев Д. Г., Гамидов С. И., Овчинников Р. И. Фармакотерапия эректильной дисфункции // Российский медицинский журнал. Том 9, № 23. — 2001.
- Мазо Е.Б., Жуков О. Б., Зубарев А. Р. Неинвазивный способ модуляции эрекции в ультразвуковой диагностике васкулогенной эректильной дисфункции // Русский Медицинский Журнал. 2002. — Том 10, N8−9.-С. 418−420.
- Николаев А.Н., Лозартан и половая функция при гипертонии // Рус. мед. журн. -2001, № 13−14.-С. 14−17.
- Пушкарь Д.Ю., Сегал A.C., Багаев А. Г., Носовицкий П. Б. Иохимбин в терапии эректильной дисфункции.//Урология. 2002. — № 6. -С. 34−37.
- Пушкарь Д.Ю., Тевлин К. П., Сидоров Д. В., Путиловский М. А. Эректильная дисфункция: принципы диагностики и новое в медикаментозном лечении // Фарматека. 2002. — № 10 (61). — С. 61−68.
- Пушкарь Д.Ю., Эль-Мазбух A.M. Исследование и объективизация состояний копулятивной функции у мужчин при использовании опросников. М. — 2002. — С. 6−10.
- Серов В.В., Пальцев М. А. Патологическая анатомия. М.: Медицина, 1998. — 96 с.
- Хамди Ф.К., Карретеро П., Перрен П. Влияние возраста, заболеваний и приема лекарств на сексуальную активность мужчин в странах Европы // Медицинские новости. 1997. — N 2. — С. 659−670.
- Хэкетт Дж. Ведение больных с нарушениями эрекции // Лечащий врач. 1999. — № 1.-С. 8−11.
- Шляхто Е.В. Особенности применения Виагры в кардиологической практике // Артериальная гипертензия. 2000. — № 1. -С. 62−64.
- Щеплев П. А., Семин Б. А. Фармакотерапия эректильной дисфункции//Андрология и генитальная хирургия-2001 -№ 1 С. 11−15.
- Щеплев П.А., Верткин А. Л., Сегал A.C. Эректильная дисфункция: причины возникновения, диагностика, лечение: Методические рекомендации // М., 2000. № 4. — 29 с.
- Щеплев П.А., Верткин А. Л., Тополянский A.B. Жиленко В. В. Атеросклероз, артериальная гипертензия, лекарственные средства и ЭД // Лечащий врач. 2001. — № 2. — С. 4−6.
- Щеплев П.А., Верткин А. Л., Тополянский А. В., Жиленко В. В., Носовицкий П. Б. ЭД у кардиологических больных // Лечащий врач.2002.-№ 3.-С. 16−20.
- Щеплёв П.А., Тополянский А. В., Жиленко В. В., Носовицкий П. Б. Эректильная дисфункция и сердечно-сосудистые заболевания // Медицинская кафедра. № 2. — 2002.
- Achour S., Laffont I., Boyer F., Boiteau F., Dizien O. Intracavernous injections in the treatment of erectile dysfunction in spinal cor imjured patients: experience with 36 patients // Ann. adapt. Med. Phys. 2001. -Vol. 44, N l.-P. 35−40.
- Alici В., Gumustas M.K., Ozkara H., Akkus E., Demirel G., Yencilek F., Hattat H. Apoptosis in the erectile tissues of diabetic and healthy rats // Brit. J. Urol. Int. 2000. — Vol. 85, N 3. — P. 326−329.
- Amar E. Value of intra-urethral prostaglandin Ej for the treatment erectile dysfunction // Contracept. Fertil Sex. 1999. — Vol. 27, N 7−8. — P. 548−552.
- Anglin G., Iglesias J., Toulouse K. Efficacy and safety of 1С 351 treatment of erectile dysfunction // Int. J. Impt. 2001. — Vol. 12, Suppl. 3. — P. 75−80.
- Anonymous. Vaseretic Tables, Physician’s Desk Reference. -1998, 52: Merck and Co., Inc/1768.
- Aranda P., Ruilope L.M., Calvo C., Luque M., Coca A., Gil de Miguel A. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study // Am. J. Hypertens. 2004. -Мщд. 17, N2.-P. 139−145.
- Bai W.J., Wang X.F., Jiang X.T., Qu H.W., Zhu J.C. Therapeutic choices of penile erectile dysfunction // Zhonghua Nan Ke Xue. 2002. -Vol.8, N5.-P. 332−334.
- Bancroft J. Central inhibition of sexual response in the male: a theoretical perspective // Neurosci Biobahav. Rev. — 1999. — Vol. 23, N 6. P. 763−784.
- Bansal S. Sexual dysfunction in hypertensive men. A critical review of the literature // Hypertension. 1988. — Vol. 29. — P. 1−10.
- Baskin H.J. Endocrinological evaluation of impotence // South Med. J. 1989. — Vol. 82. — P. 446−449.
- Benet A.E., Melman A. The epidemiology of erectile dysfunction // Urol. Clin. North Amer. 1995. — Vol. 22. — P. 699−709.
- Brock G.B. Towards optimal ED management: educational forum // Canad. J. Urol. 2001. — Vol. 8, N6.-P. 1419−1420.
- Brock G.B., McMahon C.G., Chen K.K., Costigan T., Shen W., Watkins V., Anglin G., Whitaker S. Efficacy and safety of tadalafll for the treatment of erectile dysfunction: results of integrated analyses // J Urol.-2002.-Vol.168, N 4 Pt l.-P. 1332−1336.
- Broekman C.P.- Haensel S.M.- Van de Ven L.L.- Slob A.K. Bisoprolol and hypertension: effects on sexual functioning in men // J. Sex. Marital Ther. 1992. -Vol. 29. — P. 325−331.
- Bulpitt C.J., Beevers D.G., Butler A. et al. The effects of antyhypertensive drugs on sexual function in men and women: a report from the DHSS hypertension care computing project (DHCCP) // J. Hum. Hypertens. 1989. — Vol. 3. — P. 53−56.
- Burchardt M, Burchardt T, Baer L, Kiss AJ, Pawar RV, Shabsigh A, de la Taille A, Hayek OR, Shabsigh R. Hypertension is associated with severe erectile dysfunction. J Urol. 2000 Oct- 164(4): 1188−91
- Burchardt M., Burchardt T., Baer L. v Kiss A.J., Pawar R.V., Shabsigh A., de la Taille A., Hayek O.R., Shabsigh R. Hypertension is associated with severe erectile dysfunction // J. Urol. 2000. — Vol. 164, N 4. -P. 1188−1191.
- Cappelleri J.C., Rosen R.C., Smith M.D., Mishra A., Osterloh I.H. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function // Urology. 1999. — Vol. 54. — P. 346−351.
- Caro J., Vidal J., Vicente J. et al. Sexual dysfunction in hypertensive patients treated with losartan // J. Med. Sci. 2001. — Vol. 321. — P. 336−341.
- Cellek S., Rodrigo J., Lobos E. et al. Selective nitrergic neurodegeneration in diabetes mellitus a nitric oxide-dependent phenomenon // Br. J. Pharmacol. — 1999. — Vol. 128, N 8. — P. 1804−1812.
- Chang S.W., Fine R. et al. The impact of diuretic therapy on reported sexual function // Arch. Intern. Med. 1991. — Vol. 151. — P.2402−2408.
- Chen J. Godschalk M.F. Is a second injection of vasoactive medication necesary during color duplex doppler evaluation of young pationst with veno-occlusive erectile dysfunction? // Urology. 2000. — Vol. 55, N 6. -P.927−930.
- Chen J., Godschalk M.F. Combining intracavernous injection and external vacuum as treatment for erectile dysfunction // J. Urol. 1995- 153: 1482−1488.
- Chen J., Godschalk M.F. RigiScan versus snap gauge band measurements: is the extra cost justifiable? // Inter. J. Impot. Res. 1999. -Vol. 11, N6.-P. 315−318.
- Chiang C.E., Luk H.N., Wang T.M., Ding P.Y. Effects of sildenafil on cardiac repolarization // Cardiovasc. Res. 2002. — Vol. 55, N (2. — P. 290 299.
- Corbin J.D., Francis S.H. Pharmacology of phosphodiesterase-5 inhibitors // Int. J. Clin. Pract. 2002. — Vol. 56, N 6. — P.453−459.
- Cornud F., Amar E., Hamida K., Thiounn N., Helenon O., Moreau J.F. Imaging in male hypotertitily and impotence // Brit. J. Urol. Int. 2000. — Vol. 86, Suppl. l.-P. 153−163.
- Croog S.H., Levine S., Sudilovsky A., Baume R.M., Clive J. Sexual symptoms in hypertensive patients. A clinical trial of antihypertensive medications//Arch. Intern. Med. 1988. — Vol. 29. — P. 788−794.
- Cuellar de Leon A.J., Ruiz Garcia V., Campos Gonzalez J.C., Perez Hoyos S., Brotons Multo F. Prevalence erectile dysfunction in patients with hypertension. // Med Clin (Bare). 2002. — Vol. 119, N 14. — P. 521−526.
- Derby C.A., Mohr B.A., Goldstein I., Feldman H.A., Johannes C.B., McKinlay J.B. Modifiable risk factors and erectile dysfunctions: can lifestyle changes modify risk? // Urology. 2000. — Vol. 56, N 2. — P.303−306.
- Derby C.A., Barbour M.M., Hume A.L., McKinlay J.B. Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort // Pharmacotherapy. 2001. — Vol. 21, N 6. — P. 676−683.
- Derouet H., Caspari D., Rohde V., Rommel G., Ziegler M. Treatment of erectile dysfunction with external vacuum devices // Andrologia. 1999. — Vol. 32, Suppl. l.-P. 89−94.
- Dmitriev D. G, Gamidov S.I., Mazo E.B., Ovchinnikov R.I. A new approach to raising the efficiency of drug therapy for erectile dysfunction // Ter. Arkh. 2002. — Vol. 74, N 10. — P. 75−77.
- Due D.L., Giguere G.C., Plachetka J.R. Postmarketing comparisonof labetalol and propranolol in hypertensive patients // Clin. Ther. 1986. — Vol. 8, N6.-P. 624−631.
- Dutta T.C., Eid J.F. Vacuum constriction devices for erectile dysfunction: a long-term, prospective study of patients with mild // Urology -1999. Vol. 54, N 5. — P.809−893.
- Eardley I., Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract. 2002. Vol. 56, N 4. — P. 300−304.
- Editorial. Apomorfine (TAP holdings), 6a beta-adorphine-10,11-diol hydrochloride hemihydrate, apomorphine hydrochloride, spontane, Uprima //Drugs R.D. 1998. — Vol. 2, N6.-P. 415−416.
- Ekman P. et al. Optimizing the therapeutic approach of transuretheral alporostadil // Brit. J. Urol. 2000. — Vol. 86, N 1. — P. 68−74.
- Erbagci A., Yagci F., Sarica K., Ozbek E., Topcu O. Evaluation and therapeutic regulation of erectile dysfunction with visual stimulation test. An objective approach by using sildenafil citrate test // Urol Int. 2002. — Vol. 69, N 1.-P. 21−26.
- Feldman H.A., Goldstein I., Hatzichristou D.G., Krane R.J., McKinlay J.B. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study // J. Urol. 1994. — Vol. 151. — P. 151 154.
- Ferrario CM, Levy P. Sexual dysfunction in patients with hypertension: implications for therapy // J Clin Hypertens (Greenwich). — 2002. Vol. 4, N 6. — P. 424−432.
- Fishbain D.A. Impact of sildenafil on male erectile disorder due to psychological factors // Can. J. Psychiatry. 2000. — Vol. 45, N 1. — P.85−86.
- Fogari R., Zoppi A. Effects of antihypertensive therapy on sexual activity in hypertensive men // Curr Hypertens Rep. 2002. — Vol. 4, N 3. — P. 202−210.
- Fogari R., Corradi I., Poletti L. et al. Sexual activity in hypertensive males treated with valsartan or Carvedilol. A cross-over study // J. of Hypertension. 1999. — Vol. 17 (Suppl. 3). — S 65.
- Fogari R., Zoppi A. Effects of antihypertensive therapy on sexual activity in hypertensive men. Curr. Hypertens. Rep. 2002. — Vol. 4, N 3. — P. 202−210.
- Fogari R., Zoppi A., Corradi L. et al. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study // Am. J. Hytertens. — 1998. Vol. 11.-P. 1244−1247.
- Fogari R., Zoppi A., Poletti L., Marasi G., Mugellini A., Corradi L. Sexual activity in hypertensive men treated with valsartan or Carvedilol: a crossover study // Am. J. Hypertens. 2001. — Vol. 14, N 1. — P. 27−31.
- Fogarti R., Corradi I., Poletti L. et al. Sexual activity in hypertensive males treated with valsartan or Carvedilol: A cross-over study // J. Hypertens. 1999. — Vol. 17, Suppl. 3. — P.65.
- Folkow B. 'Structural factor' in primary and secondary hypertension // Hypertension. 1990. — Vol. 16. — P. 89−101.
- Franzen D, Metha A, Seifert N, Braun M, Hopp HW. Effects of beta-blockers on sexual performance in men with coronary heart disease. A prospective, randomized and double blinded study // Int J Impot Res. 2001. — Vol. 13, N 6. — P. 348−351.
- Furst G., Miller V., Cohnen M. Venous incompletence in erectile dysfunction: Evaluation with color-coded duplex sonography and cavernosometry // Eur. Radiol. 1999. — Vol. 9, N 1. — P.35−41.
- Gao C.G., Ge J.P., Chen L.S. The situation of sildenafil in the treatment of men with erectile dysfunction // Zhonghua Nan Ke Xue. 2002. -Vol. 8, N4.-P. 302−304.
- Giuliano F., Allard J. Apomorphine SL (Uprima): preclinical and clinical experiences learned from the first central nervous system-acting ED drug // Int J Impot Res. 2002. — Vol. 14, Suppl 1. — S53−6.
- Giuliano F., Chevret-Measson M., Tsatsaris A., Reitz C., Murino M., Thonneau R Prevalence of erectile dysfunction in France: Results of an epidemiological survey of a representative sample of 1004 men // Eur. Urol. -2002. Vol. 42. — P. 382−389.
- Goldstein I. Efficacy and safety of oral phentolamine (Vasomax) for the treatment of minimal erectile dysfunction // J. Urol. 1998. Vol. 15, N 5.-P.240.
- Goldstein I., Lue T.F., Padma-Nathan H. et al. Oral sidenatil in the treatment of erectile dysfunction // N. Engl. Med. 1998. — Vol. 338. — P. 13 971 403.
- Gresser U., Gleiter C.H. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil—review of the literature // Eur J Med Res. 2002. — Vol. 7, N 10. — P. 435−446.
- Guimaraes A.C. et al. Use of sildenafil of patients with cardiovascular disease // Arq. Bras. Cardiol. 1999. — Vol. 73, N 6. — P.515−526.
- Hale T.M., Okabe H., Heaton J.P., Adams M.A. Antihypertensive drugs induce structural remodeling of the penile vasculature // J. Urol. 2001. -Vol. 166.-P. 739−745.
- Heaton J.P. Central neuropharmacological agents and mechanism in erectile dysfunction: the role of dopamine // Neurosci. Biobehav. Rev. -2000. Vol. 24, N 5. — P.561−569.
- Heaton JP, Dean J, Sleep DJ. Sequential administration enhances the effect of apomorphine SL in men with erectile dysfunction // Int J Impot Res. 2002. — Vol. 14, N 1. — P. 61−64.
- Hong E.K. et al. Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomu (RRP) // Int. J. Impot. Res. 1999. — Suppl. 1. — S. 15−22.
- Jackson G. et al. A systematic approach to erectile dysfunction in the cardiovascular patient: a consensus statement // Int. J. Clin. Pract. 1999. -Vol. 53, N6.-P. 445−451.
- Jackson G., Giuilano F. Moderator’s introduction // Eur Heart J Suppl. 2002. — Vol. 4, Suppl H. — P. 1−6
- Jaffe A., Chen Y., Kisch E.S., Fischel B., Alon M., Stern N. Erectile dysfunction in hypertensive subjects. Assessment of potential determinants // Hypertension. 1996.- Vol. 28, N 5. — P. 859−862.
- Jardin A., Wagner G., Khoury S., Giuliano F., Padma-Nathan H., Rosen R., eds. Recommendations of the 1st International Consultation on Erectile Dysfunction // Health Publications Ltd, Oxford, 2000.
- Jonler M., Goon T., Stone D. The effect of age, ethnicity and geographical location on impotence // Brit. J. Urol. — 1995. Vol. 75. — P. 651 655.
- Jungwirth A. Physiology and pathophysiology of erectile dysfunction // Wien. Med. Wochenschr. 2000. — Bd. 50, N 1−2. — S.4−7.
- Kassouf W, Carrier S. A comparison of the International Index of Erectile Function and erectile dysfunction studies // BJU Int. 2003. — Vol. 91, N 7. — P. 667−669.
- Khan M.A., Morgan R.J., Mikhailidis D.P. The choice of antihypertensive drugs in patients with erectile dysfunction // Curr. Med. Res. Opin. 2002. — Vol. 18, N 2. — P. 103−107.
- Khan MA, Raistrick M, Mikhailidis DP, Morgan RJ. MUSE: clinical experience // Curr Med Res Opin. 2002. — Vol. 18, N 2. — P. 64−67.
- Kim H.S. et al. Sexual dysfunction in men with paraparesis in lumbar burst fractures // Spine. 2000. — Vol. 25, N 17. — P.2187−2190.
- Kim Y.C. Algorithm for diagnosis and treatment of erectile dysfunction in the era of sildenafil citrate // Int. J. Androl. 2000. — Vol.23, Suppl. 2.-P. 85−86.
- Kleinmann K.P. et al. A new surrogate variable for erectile dysfunction status in the Massachusetts male aging study // J. Clin. Epidemiol. 2000. — Vol. 5, N 1. — P. 71−78.
- Kloner R.A., Mitchell M.I., Bedding A., Emmick J. Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil. J. Urol. 2002. — Vol. 167(4).-P. 176−177.
- Kloner R.A., Speakman M. Erectile dysfunction and atherosclerosis. Curr. Atheroscler. Rep. 2002. — Vol. 4, N 5. — P. 397−401.
- Kloner R.A., Watkins VS., Costigan T.M., Bedding A., Mitchell M.I., Emmick J. Cardiovascular profile of tadalafil. a new PDE5 inhibitor. J. Urol. 2002.-Vol. 167(4).-P. 176.
- Klyde B. Hormonal cases of male sexual dysfunction // Management of Impotence and Intertility. New York: Lippincott Comp., 1994. — P.115−121.
- Ko D.T., Hebert P.R., Coffey C.S., Sedrakyan A., Curtis J.P., Krumholz H.M. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002. — Vol. 288, N 3. — P. 351−357.
- Kolodny R.C., Kahn C.P. Sexual dysfunction in diabetes // Diabetes 1974-Vol. 23. — P.306−309.
- Kongkanand A. Prevalence of erectile dysfunction in Thailand: Thai erectile dysfunction Epidemiological Study Group // Int. J. Androl. -2000.-Vol.23, Suppl. 2. -P.77−80.
- Kuan J., Brock G. Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction // Expert Opin Investig Drugs. 2002. — Vol. 11, N 11. — P. 1605−1613.
- Kung C.F., Luscher T.F. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta // Hypertension. 1995. -Vol. 25.-P. 194−200.
- Kuritzky L. Counseling the patient with erectile dysfunction: a primary care physician perspective // J Am Osteopath Assoc. 2002. — Vol. 102, 12 Suppl 4. — S7−11.
- Laumann E.O. et al. The epidemiology of erectile dysfunction: results from the National Health and Social Life Survey // Int. J. Impot. Res. -1999.-Vol. 11, Suppl. l.-P. S60-S64.
- Li J.S., Sharif! A.M., Schiffrin E.L. Effect of AT, angiotensin-receptor blockade on structure and function of small arteries in SHR // J/ Cardiovasc. Pharmacol. 1997. — Vol. 30. — P. 75−83.
- Lin I.S. et al. Novel image analysis of corpus cavernous tissue in impotent men // Urology. 2000. — Vol.55, N 2. — P.252−256.
- Linder L., Kiowski W., Buhler F.R., Luscher T.F. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response in essential hypertension // Circulation. -1990.-Vol. 81.-P. 1762−1767.
- Linet O.I., Ogrinc F.G. Alprostadil Study Group. Efficacy and safety of Alprostadil in men with erectile dysfunction // N. Engl. J. Med. -1996,-Vol. 334. -P.873−877.
- Llisterri J.L., Lozano Vidal J.V., Aznar Vicente J., Argaya Roca M., Pol Bravo C., Sanchez Zamorano M.A., Ferrario C.M. Sexual dysfunction in hypertensive patients treated with losartan // Am. J. Med. Sci. 2001. -Vol. 321? N5. -P. 336−341.
- Lowentritt B.H. et al. Sildenafil citrate after radical retropubic prostatectomy // J. Urol. 1999. — Vol. 162, N 5. — P. 1614−1617.
- Lue T.F. A study of sidenafil (Viagra), a new oral agent for the treatment of male erectile dysfunction // J. Urol. 1997. — Vol. 157. — P.701 A.
- Lue T.F. Erectile dysfunction // N. Engl. J. Med. 2000. -Vol.342, N 24. — P.1802−1813.
- Maggi M. et al. Erectile dysfunction: from biochemical pharmacology to advances in medical therapy // Eur. J. Endocrinol. 2000. -Vol.143, N 2.-P.143−154.
- Magoha G.A. Sildenafil (Viagra) in the treatment of male erectile dysfunction in Nairobi // East. Amer. Med. J. 2000. — Vol.77, N 2. — P.76−99.
- Marley J.E. Safety and efficacy of nifedipine 20 mg tablets in hypertension using electronic data collection in general practice // J. R. Soc. Med. 1989. — Vol. 82, N 5. — P. 272−275.
- Martin C. et al. Genitourinary changes in multiple sclerosis: the need for a urodynamic study // Rev. Neurol. 2000. — Vol.30, N 7. — P.643−648.
- Martin-du-Pan R. Do viagra and fertilization in vitro announce the end of etiologic treatments in andrology // J. Gynecol. Obstet. Biol. Reprod. -2000. Vol.29, N 4. — P.345−359.
- Marumo K, Nakashima J, Murai M. Age-related prevalence of erectile dysfunction in Japan: assessment by the International Index of Erectile Function // Int J Urol. 2001. — Vol. 8, N 2. — P. 53−59.
- Marumo K. et al. Effect of aging and diseases on male sexual function assessed by. the International Index of Erectile Function // Nippon Hiayokika Gakkai Zasshi. 1999. — Vol. 90, N 12. — P.911−919.
- Mazo E. B, Dmitriev D.G., Gamidov S.I., Ovchinnikov R.I. Sildenafil and alprostadil in the combined drug therapy of erectile dysfunction // Urologiia. 2002. — N 3. — P. 39−43.
- McKinlay J.B. et al. International differences in the epidemiology of male erectile dysfunction // Int. J. Clin. Pract. 1999. — Suppl.l. — P.102−135.
- Melis M. et al. EP 60 761 and EP 50 885, two hexarelin analogues, induce penile erection in rats // Eur. J. Pharmacol. 2000. — Vol. 404. — P. 137 143.
- Melis M.R., Argiolas A. Dopamine and sexual behavior // Neuroscien. Behav. Rev. 1995. — Vol. 19, N 1. — P. 19−38.
- Mellinger B.C., Voughan E.D. Erectile dysfunction // J. Urol. -1990. Vol. 144, N 4. — P.894−896.
- Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction // J Urol. 1999. — Vol. 161. -P. 5−11.
- Meuleman E.J., Diemont W.L. Investigation of erectile dysfunction. Diagnostic testing for vascular factors in erectile dysfunction // Urol. Clin. North. Am. 1995. — Vol. 22, N 4. — P. 803−819.
- Meuleman E.J., Donkers L.H., Robertson C., Keech M., Boyle P., Kiemeney LA. Erectile dysfunction: prevalence and effect on the quality of life Boxmeer study // Ned. Tijdschr. Geneeskd. 2001. -Vol. 145. — P. 576−581.
- Meuleman E.J., Kingma J.H. Drug treatment of erection disorders in patients with cardiovascular disease // Ned. Tijdschr. Geneeskd. 2001. — Vol. 145, N 4. — P. 167−171.
- Meuleman E.J. Prevalence of erectile dysfunction: need for treatment? // Int J Impot Res. 2002. — Vol. 14, Suppl 1. — S22−28.
- Mickley H. Incidence and treatment of sexual dysfunction in heart disease. // Ugeskr Laeger. 2002. — Vol. 164, N 41. — P. 4760−4764.
- Migaleddu V., Virgilio G., Cucciari P., Retanda L., Carboni C., Piras P., Carboni M., Canalis G.C. Doppler color ultrasonography in patients with erectile dysfunction. //Arch Ital Urol Androl. 2000 Dec-72(4):371−5.
- Mock K. Epidemiology and age-related risk factors of erectile dysfunction // Wien. Med. Wochenschr. 2000. — Vol. 150, N 1−2. — P.2−3.
- Montorsi F., Perant D., Anchisi D. Apomorphine-induced brain modulation during sexual stimulation // ESU Cource diagnosis and management of erectile dysfunction. Milano. 2002. — P.20−23.
- Morales A. Yohimbine and erectile dysfunction: the facts // Int. J. Impot. Res. 2000. — Vol. 12, Suppl. 1. — S.70−74.
- Morgentaler A. Male impotence // Lancet. 1999. — Vol. 354, N9191.- P. 1713−1718.
- Mulcahy J.J. Erectile dysfunction is the incidence increasing? // J. Urol. — 2000. — Vol. 163, N 2. — P. 471.
- Muller S.C., el-Damanhoury H., Ruth J., Lue T.F. Hypertension and impotence //Eur. Urol. 1991. — Vol. 19, N 1. — P. 29−34.
- Murray F.T., Wyss H.U., Thomas R.G. et al. Gonadal dysfunction in diabetic men with organic impotence // J. Clin. Endocrinol. Metab. 1987 — Vol. 65. -P.127−135.
- Mydlo J.H. et al. Initial results utilizing combination therapy for patients with a subortimal response to either alprostadil or sildenafil monotherapy // Eur. Urol. 2000. — Vol. 38, N 1. — P.30−34.
- Nagao K. et al. One-day penile prostesis surgery by penile block // Int. J. Urol. 2000. — Vol. 7, Suppl. — P. S56-S60.
- Nagase M., Shimosawa T., Ando K., Fujita T. Local renin-angiotensin system in sympathetic overactivity of spontaneously hypertensive rats//Hypertens. Res. 1996.-V61. 19.-P. 171−177.
- Nehra A. et al. Rationale for combination therapy of intraurethral prostaglandin E (l) and sildenafil in the salvage of erectile dysfunction patientsdesiring noninvasive therapy // Int J Impot Res. 2002. — Vol. 14, Suppl 1. -S38−42.
- Nurnberg H.G. et al. Efficacy of sidenafil citrate for the treatment of erectile dysfunction in men taking serotonin reuptake inhibitors // Psychiatry. 2001. — Vol.158, N 1. — P. 192−198.
- Nusbaum MR. Erectile dysfunction: prevalence, etiology, and major risk factors // J Am Osteopath Assoc. 2002. — Vol. 102, 12 Suppl 4. -Sl-6.
- Okabe H., Hale T.M., Kumon H., Heaton J.P., Adams M.A. The penis is not protected: in hypertension there are vascular changes in the penis which are similar to those in other vascular beds // Int. J. Impot. Res. 1999. -Vol. 11.-P. 133−140.
- Ormrod D., Easthope S.E., Figgitt D.P. Vardenafil // Drugs Aging. 2002. — Vol. 19, N 3. — P. 217−227- discussion 228−9.
- Padma-Nathan H. Viagra (sildenafil citrate) in clinical practice // Int. J. Clin. Pract. 1999. — Vol. 102, Suppl. — P.2−5.
- Padma-Nathan H., Eardley I., Kloner R.A., Laties A.M., Montorsi F. A 4-year update on the safety of sildenafil citrate (Viagra) // Urology. -2002. Vol. 60, Suppl 2. — P. 67−90.
- Padma-Nathan H., Giullano F. Oral drug therapy for erectile dysfunction // Urol. Clin. North Amer. 2001. — Vol. 28. — P. 321−334.
- Padma-Nathan H., Hellstom W.I.G., Kaiser F.E. et al. Treatment of men with erecule dysfunction with transurethral alprostadil // N. Eng. J. Med. 1997.-Vol. 336.-P.l-7.
- Padma-Nathan H., Porst H., Rosen R.C. Tadalafil provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction. // Munich: Abstracts of the 3rd World Congress of the aging men. 2000. — P.234.
- Patterson B., Bedding A., Jewel H. The effect of intransic and extrinsic factors on the pharmacokinetic properties of tadalafil. Munich: Abstracts of the 3rd World Congress of the aging men, 2000. — P.234.
- Peled R. et al. Recording natural erections following injuries and insurance claims: cost-effectiveness // Harefuah. 1999. — Vol.36, N 6. -P.432−434.
- Persson G. Five-year mortality in a 70-year-old urban populatiol in relation to psychiatric diagnosis, personality, sexuality am early parental death. Acta Psychiatr. Scand. 1981. — Vol. 64. — P. 244−253.
- Pfizer. Viagra (sildenafil) h M., 2000. — 52 c.
- Porst H. IC351 (tadalafil, Cialis): update on clinical experience // Int J Impot Res. 2002. — Vol 14, Suppl 1. — P57−64.
- Porst H. Vadenafil improved erectile function regadless of age, baseline severity, and antihypertensive medication // The 3rd World Congress of the aging male. Munich, 2000. — Abstracts 61. — P.233.
- Porst H., Vardenafil demonstrated similar efficacy and tolerability among older and younger patients with marginel differences in PK characteristics between age groups // The 3rd Word Congress of the aging male. // Munich, 2000. -Abstracts 62. P.233.
- Price D.E., Cooksey G., Jehu D. The management of impotence in diabetic men by vacuum tumescent therapy. // Diabetic Med. 1991, N8. -P.964−967.
- Prisant L.M. Fixed low-dose combination in first-line treatment of hypertension // J. Hypertens. 2002. — Vol. 20, Suppl 1. — S11−19.
- Purvia K. et al. Intracavernosal therapy for erectile failure-impact of treatment and reasons for drop-out and dissatisfaction // Int. J. Impot. Res. -1999. Vol. 11. — N 5. — P.287−299.
- Ralph D., McNicholas T. UK management guidelines for erectile dysfunction. BMJ. 2000. — Vol. 321, N 19. — P. 499−503.
- Ribe S.N. et al. Acceptability of auto-injection of vasoactive drugs in the treatment of erectile dysfunction // Arch. Exp. Urol. 1999. — Vol.52, N 9. -P.973−977.
- Rodriguez V.L. et al. Current status of the treatment of organic erectile dysfunction // Acta Urol. Exp. 2000. — Vol.24, N 1. — P.76−88.
- Rosen R.C., Cappelleri J.C., Gendrano N. 3rd. The International Index of Erectile Function (IIEF): a state-of-the-science review // Int. J. Impot. Res. 2002. — Vol. 14, N 4. — P. 226−244.
- Roy C. et al. Duplex Doppler sonography of the flaccid penis: potential role in the evaluation of impotence // J. Clin. Ultrasound. 2000. — Vol.28, N 6. — P.290−294.
- Sadovsky J.K. et al. New treatments for erectile dysfunction // Int.J.Clin.Pract. 2001. — Vol.85. — P. 115−128.
- Shabsigh R. et al. Intracavernous alpostadil alfadex (Edex/Viridal) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra) // Urology. 2000. — Vol. 55, N 4. — P.477−480.
- Shirai M. et al. Prevalence and correlates of erectile dysfunction in Japan // Int. J. Clin. Pract. 1999. — Vol.102. Suppl. — P.36−39.
- Siu S.C. et al. Prevalence of and risk factors for erectile dysfunction in Hon Kong diabedic patients // Diabet. Med. 2001. — Vol. 18, N 9. — P.732−738.
- Slag M.F., Morley J.E., Elson M.K., et al. Impotence in medical clinic outpatients // JAMA 1983. — Vol. 249 — P. 1736−1740.
- Sommer F., Engelmann U. Vardenafil Bayer Yakuhin // Curr Opin Investig Drugs. 2002. — Vol. 3, N 4. — P. 607−613.
- Stief C.G. Oral agents: phosphodiesterase 5-inhibitors. Basic and Clinic // ESU Course diagnosis and management of erectile dysfunction. -Milano, 2002.-P.31−39.
- Suzuki H., Tominaga T., Kumagai H., Saruta T. Effects of first-line antihypertensive agents on sexual function and sex hormones // J. Hypertens. Suppl.-1988.-Vol. 29. S649−651.
- Taddei S, Virdis A, Mattel P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension // Hypertension. 1993. — Vol. 21. — P. 929−933.
- Taddei S., Virdis A., Ghiadoni L., Magagna A., Salvetti A. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension // Hypertension. 1997. — Vol. 29. — P. 274−279.
- Tan H.M. New therapies for erectile dysfunction // Int. J. Androl. 2000. — Vol. 23, Suppl. 2 — P.87−88.
- Tedesco M.A., Ratti G., Mennella S. et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am. J. Hypertens. 1999. — Vol. 12(11 pt 1). — P. 11 301 134.
- Thai E. An epidemiological study of erectile dysfunction in Thailand // J. Med. Assoc. Thai. 2000. — Vol. 83, N 8. — P.872−879.
- Thomas J.A. Pharmacological aspects of erectile dysfunction // Jpn. J. Pharmacol. 2002. — Vol. 89, N 2. — P. 101−112.
- Toblli J.E., Stella I., Inserra F., Ferder L., Zeller F., Mazza O.N. Morphological changes in cavernous tissue in spontaneously hypertensive rats // Am. J. Hypertens. 2000. — Vol. 13, N 6, Pt 1. — P. 686−692.
- Tordjemann G. Clinical investigations for erectile disorders // Contracept. Fertil. Sex. 1999. — Vol. 27, N 11. -P.755−758.
- Udelson D. et al. Axial Penile Regiscan does not predict functional erection in individe patients // Int. J. Impot. Res. 1999. — V. l 1, N 6. -P.327−337.
- Valji K., Bookstein J.J. Diagnosis of arteriogenic impotence: efficacy of duplex sonography as a screening tool // AJR Am. J. Roentgenol. — 1993. Vol. 160, N 1. — P. 65−69.
- Van Bortel L.M., Struijker-Boudier H.A., Safar M.E. Pulse pressure, arterial stiffness, and drug treatment of hypertension //Hypertension. -2001.-Vol. 38, N4.-P. 914−921.
- Vardi Y., Klein L., Nassar S., Sprecher E., Gruenwald I. Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men // Urology. 2002. — Vol. 59, N 5. — P. 747−752.
- Vardi Y., Sprecher E., Gruenwald I. Logistic regression and survival analysis of 450 impotent patients treated with injection therapy: long-term dropout parameters // J. Urol. 2000. — Vol. 163, N 2. — P.467−470.
- Virag R. Indications and early results of sildenafil (Viagra) in erectile dysfunction // Urology. 1999. — Vol.54, N 6. — P. 1073−1077.
- Virag R. Intracavernosal injection papaverine for erectile failure // Lancet. 1982. N 2. — P.938−939.
- Vitezic D., Pelcic J.M. Erectile dysfunction: oral pharmacotherapy options // Int. J. Clin. Pharmacol. Ther. 2002. — Vol. 40, N 9.-P. 393−403.
- Vives S.A. et al. Patients response to and assessment of intracavernous drug injection and vacuum // Acta Urol. Exp. 2001. — Vol. 24, N3.-P.231−234.
- Wagner O., Montorsi F., Auerbach S. Sidenafil citrate (Viagra) improves erectile function in elderly patients // J. Genitourology. Biol. Sci. — 2001.- V.56.-P.113−119.
- Walczak M.K., Lokhandwala N., Hodge M.B., Guay A.T. Prevalence of cardiovascular risk factors in erectile dysfunction // J Gend Specif Med. 2002. — Vol. 5, N 6. — P. 19−24.
- Walsh P.C. Marschke P. Ricker D. Burnett AL. et al. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy // Urology. 2000. — Vol.55, N 1. -P.58−61.
- Wang Z.L., Li B., Yan J.Z., Dong S.G. Prostaglandin El versus sildenafil in the management of erectile dysfunction // Zhonghua Nan Ke Xue. 2002. — Vol. 8, N 3. — P. 198−200.
- Wayne J.G. et al. Transuretheral approstadil for the treatment of erectile dysfunction: long term safety profile // 2nd Meeting of the European Society for Impotense Research, Madrid 1−4 October, 1997.
- Wespes E, Amar E, Hatzichristou D, Montorsi F, Pryor J, Vardi Y. Guidelines on erectile dysfunction // Eur Urol. 2002. — Vol. 41, N 1. — P. 1−5.
- Wilson S.K., Delk J.R. Impotence (it's reversible). Amsterdam: VanBuren, 1995.-80 p.
- Young JM. Vardenafil // Expert Opin. Investig. Drugs. 2002. -Vol. 11, N 10. -P. 1487−1496.
- Zusman R.M., Morales A., Glasser D. Overall cardiovascular profile of sildenafil citrate // Amer. J. Cardiol. 1999. — Vol. 83. — P.35C-44C.